121 related articles for article (PubMed ID: 37352544)
21. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
22. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Pfeiffer RM; Wheeler W; Yeager M; Chanock S; Tucker MA; Goldstein AM
Int J Cancer; 2009 Dec; 125(12):2912-7. PubMed ID: 19626699
[TBL] [Abstract][Full Text] [Related]
23. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds.
Hashemi J; Linder S; Platz A; Hansson J
Melanoma Res; 1999 Feb; 9(1):21-30. PubMed ID: 10338331
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A variants in a population-based sample of Queensland families with melanoma.
Aitken J; Welch J; Duffy D; Milligan A; Green A; Martin N; Hayward N
J Natl Cancer Inst; 1999 Mar; 91(5):446-52. PubMed ID: 10070944
[TBL] [Abstract][Full Text] [Related]
25. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27287845
[TBL] [Abstract][Full Text] [Related]
26. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Burke LS; Hyland PL; Pfeiffer RM; Prescott J; Wheeler W; Mirabello L; Savage SA; Burdette L; Yeager M; Chanock S; De Vivo I; Tucker MA; Goldstein AM; Yang XR
PLoS One; 2013; 8(8):e71121. PubMed ID: 23990928
[TBL] [Abstract][Full Text] [Related]
27. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
[TBL] [Abstract][Full Text] [Related]
28. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
29. CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial.
Arnaut JRMB; Guimarães IDS; Dos Santos ACE; Rodrigues EM; Machado JRDS; de Melo AC
Int J Dermatol; 2023 Aug; 62(8):1060-1066. PubMed ID: 37322831
[TBL] [Abstract][Full Text] [Related]
30. Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients.
Vergani E; Frigerio S; Dugo M; Devecchi A; Feltrin E; De Cecco L; Vallacchi V; Cossa M; Di Guardo L; Manoukian S; Peissel B; Ferrari A; Gallino G; Maurichi A; Rivoltini L; Sensi M; Rodolfo M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573422
[TBL] [Abstract][Full Text] [Related]
31. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
[TBL] [Abstract][Full Text] [Related]
32. Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome.
Vanneste R; Smith E; Graham G
Am J Med Genet A; 2013 Jun; 161A(6):1425-31. PubMed ID: 23613284
[TBL] [Abstract][Full Text] [Related]
33. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
34. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
[TBL] [Abstract][Full Text] [Related]
35. CDKN2A and MC1R variants found in Cypriot patients diagnosed with cutaneous melanoma.
Koulermou G; Shammas C; Vassiliou A; Kyriakides TC; Costi C; Neocleous V; Phylactou LA; Pantelidou M
J Genet; 2017 Mar; 96(1):155-160. PubMed ID: 28360400
[TBL] [Abstract][Full Text] [Related]
36. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
37. Multiplex melanoma families are enriched for polygenic risk.
Law MH; Aoude LG; Duffy DL; Long GV; Johansson PA; Pritchard AL; Khosrotehrani K; Mann GJ; Montgomery GW; Iles MM; Cust AE; Palmer JM; ; Shannon KF; Spillane AJ; Stretch JR; Thompson JF; Saw RPM; Scolyer RA; Martin NG; Hayward NK; MacGregor S
Hum Mol Genet; 2020 Oct; 29(17):2976-2985. PubMed ID: 32716505
[TBL] [Abstract][Full Text] [Related]
38. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
39. The D84E variant of the alpha-MSH receptor 1 gene is associated with cutaneous malignant melanoma early onset.
F-de-Misa R; Hernández-Jimenez JG; Carretero Hernández G; Pérez-Méndez L; Aguirre-Jaime A; Flores C; Suárez Hernández J; Perera Molinero A; Claveríe-Martín F
J Dermatol Sci; 2008 Dec; 52(3):186-92. PubMed ID: 18657399
[TBL] [Abstract][Full Text] [Related]
40. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]